Wolfgang Miesbach։ Thrombosis After Haemophilia B Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared post on LinkedIn:
”Newly reported at ISTH2026: bilateral pulmonary emboli after gene therapy for haemophilia B.
A 52-year-old man with moderately severe haemophilia B (FIX less than 2 percent), physically active, with no thrombotic risk factors, received 1 times 10 to the 12th vg per kg fidanacogene elaparvovec in a Pfizer-sponsored trial in May 2023 — twice the licensed dose of 5 times 10 to the 11th vg per kg.
For two years, his FIX activity fluctuated but was repeatedly supranormal. Then, at week 108: DVT and bilateral pulmonary emboli on CTPA, now requiring long-term anticoagulation.
Not the first thrombotic event reported after haemophilia B gene therapy: B-AMAZE (FLT180a) reported an AV fistula thrombosis at 1.28 times 10 to the 12th vg per kg, with FIX levels reaching approximately 310 percent.
Assay discrepancy, followed through week 120:
- One-stage SynthASil, local: plateau 120 to 160 percent, peaks approximately 180 percent.
- One-stage SynthASil, central: approximately 220 percent early and again near week 104, approximately 185 percent at the time of the event.
- One-stage Actin-FSL: mostly 80 to 110 percent, but three discordant spikes of 310 percent or higher, and only approximately 130 percent on the day of thrombosis.
- Chromogenic: 0.6 to 1.0 IU per mL throughout, never above the upper limit.

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series